11 GHP Biotechnology & Lifesciences Awards 2026 or more than three decades, Altasciences has partnered with sponsors to enable smarter, faster, and more confident early drug development decision-making. The integrated early-phase drug development organisation works alongside pharmaceutical, biopharmaceutical, and biotech companies to accelerate their programmes with intention by aligning nonclinical safety, clinical pharmacology, bioanalysis, and formulation and manufacturing within one organisation. Altasciences has grown steadily since its inception in 1995, earning renown for its ability to reduce development timelines by up to 40%. The company has expanded its capabilities and reach along the way, adding facilities across North America and establishing a presence in the UK. Today, Altasciences boasts nine facilities and is strategically structured to eliminate common bottlenecks that can slow early drug development. “For over 30 years, we’ve intentionally built the infrastructure, processes, and culture needed to make early-phase development more seamless and predictable for sponsors,” Marie-Hélène told us. “Our Acceleration Platform is designed to anticipate challenges, streamline transitions, and keep programmes moving efficiently, giving sponsors a simpler path forward to reach their critical inflection points faster.” While other CROs and CDMOs offer many of the same services, few are structured in such a truly intergrated and synchronised way, and none offer the same full breadth of end-to-end services. Altasciences understands that nonclinical, clinical pharmacology, bioanalysis, and manufacturing do not operate independently from one another, but are in fact aligned, and must be navigated with teams and systems that communicate in real time and operations that are centrally managed. At Altasciences, every component of early-phase drug development is brought together within one coordinated organisation. This model enables the team to expedite R&D timelines by parallel processing certain key activities, such as overlapping safety assessment with IND and CTA submission preparation and Phase I and II clinical conduct and integrated bioanalysis. In doing so, Altasciences successfully reduces development timelines and saves sponsors time, resources, and unnecessary frustration. To remain at the forefront of the early-phase drug development space, Altasciences pays meticulous attention to compliance, aligning closely with regulatory agency guidelines, including the U.S. Food and Drug Administration, Canada’s Health Products and Food Branch, the UK’s In early-phase development, sponsors are often tasked with navigating a fragmented system: coordinating multiple CROs, managing separate timelines, and bridging communication gaps between siloed teams. When combined with the rising costs of drug development, uncertainty regarding regulatory changes, and scaled-back pipelines, sponsors are feeling an immense pressure to accelerate their time to market. Enter Altasciences, a drug development organisation that removes the need for multiple service providers by offering a simplified pathway for early-phase drug development programmes. We heard more from Altasciences’ Chief Executive Officer, Marie-Hélène Raigneau, as the company is named in the Biotechnology and Lifesciences Awards 2026. Best Biopharmaceutical CRO 2026 MHRA, the European Medicines Agency, and many more, as well as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. But that’s not all; in 2025, Altasciences announced a strategic collaboration with Evidence Matters to advance AIenhanced text for regulatory writing. In doing so, it aims to generate deeper insights, improve operational efficiencies, and maintain a competitive edge. This partnership allows the company to move with the times while aligning with evolving international regulatory expectations, ultimately helping sponsors to move faster with confidence. The drug development industry is constantly evolving, and early-phase studies are becoming increasingly complex, with growing demand for early proof-of-concept exploration and the assessment of expanded datasets and multiple endpoints in first-in-human trials. Looking to the future, Altasciences is anticipating continued momentum in the number of incretin-based therapeutic (such as GLP1) programmes moving through development. To remain fast and agile for its clients, the company is actively exploring opportunities to expand its facilities and further enhance its capabilities. Each investment promises to strengthen its Acceleration Platform, streamline processes, and ensure that Altasciences continues to deliver high-quality results with speed, ease, and flexibility. “Altasciences was founded on the belief that integration, accountability, and scientific excellence can simplify early-phase drug development,” Marie-Hélène concluded. “And of course, listening to our clients remains central to our strategy. Through ongoing client engagement and the structured efforts of our Client Experience team, we continuously refine and improve the sponsor journey. “As we look ahead, our commitment to great science, patient safety, and doing things the right way will remain constant, grounded in a collaborative culture that continues to drive our success.” Contact: Julie-Ann Cabana Company: Altasciences Web Address: www.altasciences.com F
RkJQdWJsaXNoZXIy MTUyMDQwMA==